Who we are
Polyplus, part of Sartorius, is a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial scale.

An innovator in nucleic acid delivery, the legacy portfolio features process-centric transfection reagents, kits, and support services for viral and non-viral delivery. Custom plasmid vector design and plasmid and protein manufacturing were integrated into the offer in 2022 to expand the products and services portfolio to help the industry optimize process economics while meeting strict scientific and regulatory standards.

Headquartered in Europe, the Polyplus team continues to grow globally with operations in the United States and Asia. Since July 2023, Polyplus is now part of Sartorius.

Our mission
Our mission is to develop innovative solutions that enable scientists to develop breakthrough nucleic acid-based therapies that improve human health.

Founding the company
Polyplus has been driven to innovate solutions for nucleic acid delivery that power your science since January 2001. Originally named Polyplus-transfection, the company shortened the name to Polyplus in 2022, as we began to expand our focus on building our portfolio of purpose-fit solutions and services that help customers optimize upstream process economics.

Our Vision
Our vision is to help drug developers and manufacturers innovate with greater confidence and quality while reducing cost and time to market for cell and gene therapies and RNA & DNA therapeutics.